Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Empagliflozin

An antidiabetic of the gliflozin class (SGLT2 inhibitors), approved in 2014: it makes the body excrete excess sugar in the urine. Today it is also used in heart failure and chronic kidney disease. This family brings together the active ingredient, metabolites, labelled standards, other impurities and synthesis intermediates.

Did you know?In a study published in 2015 in more than 7,000 people with type 2 diabetes and cardiovascular disease, it reduced cardiovascular death compared with placebo.

EmpagliflozinGo to the active ingredient →
EmpagliflozinActive ingredientEmpagliflozinCat. No. P-E037-001CAS 864070-44-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.